$MDLN earnings report

Third quarter net sales increased 10.4% to $7.9 billion and Adjusted EBITDA increased 11.8% to $960 million; full year 2026 Organic Sales guidance was raised to 10.0% to 10.5%. AlphAI read Medline's Third Quarter and Nine Months 2026 filing as solid. 2 quarters are on record below.

Third Quarter and Nine Months 2026

AlphAI · Earnings readMDLN · Third Quarter and Nine Months 2026 · ended September 26, 2026

Third quarter net sales increased 10.4% to $7.9 billion and Adjusted EBITDA increased 11.8% to $960 million; full year 2026 Organic Sales guidance was raised to 10.0% to 10.5%.

✓Solid quarter

Double-digit sales growth, higher Adjusted EBITDA, raised Organic Sales guidance and strong nine-month cash generation were offset by lower GAAP net income, gross-margin compression, and substantial nine-month costs related to the Tracy distribution center fire.

Revenue
$7.86B
10.4 % y/y
Medline Brand segment, three months ended September 26, 2026
$3.64B
6.6 % y/y
Gross margin · GAAP
24.5 %
EPS · non-GAAP
$ 0.44

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended September 26, 2026GAAP$7.86B–10.4 %
Organic Sales, three months ended September 26, 2026non-GAAP$748M–10.5 %
Cost of goods sold, three months ended September 26, 2026GAAP$5.93B–13.2 %
Gross profit, three months ended September 26, 2026GAAP$1.93B–2.7 %
Gross margin, three months ended September 26, 2026GAAP24.5 %––
Selling, general and administrative expenses, three months ended September 26, 2026GAAP$1.26B–12.8 %
Amortization of intangible assets, three months ended September 26, 2026GAAP$176M–(0.6) %
Other operating (income) expenses, net, three months ended September 26, 2026GAAP−$10M–NM
Total operating expense, three months ended September 26, 2026GAAP$1.43B–9.5 %
Operating income, three months ended September 26, 2026GAAP$500M–(12.9) %
Operating margin, three months ended September 26, 2026GAAP6.4 %––
Income before income taxes, three months ended September 26, 2026GAAP$386M–11.9 %
Provision for income taxes, three months ended September 26, 2026GAAP$68M–NM
Net income, three months ended September 26, 2026GAAP$318M–(1.2) %
Net income margin, three months ended September 26, 2026GAAP4.0 %––
Net income attributable to Medline Inc., three months ended September 26, 2026GAAP$195M–(39.4) %
Diluted earnings per share attributable to Medline Inc., three months ended September 26, 2026GAAP$ 0.22––
Adjusted EBITDA, three months ended September 26, 2026non-GAAP$960M–11.8 %
Adjusted EBITDA Margin, three months ended September 26, 2026non-GAAP12.2 %––
Adjusted Net Income, three months ended September 26, 2026non-GAAP$577M––
Adjusted Diluted EPS, three months ended September 26, 2026non-GAAP$ 0.44––
Net sales, nine months ended September 26, 2026GAAP$22.89B–10.9 %
Organic Sales, nine months ended September 26, 2026non-GAAP$2.21B–10.7 %
Gross profit, nine months ended September 26, 2026GAAP$5.98B–6.7 %
Gross margin, nine months ended September 26, 2026GAAP26.1 %––
Operating income, nine months ended September 26, 2026GAAP$1.32B–(26.3) %
Operating margin, nine months ended September 26, 2026GAAP5.8 %––
Net income, nine months ended September 26, 2026GAAP$696M–(28.8) %
Net income margin, nine months ended September 26, 2026GAAP3.0 %––
Net income attributable to Medline Inc., nine months ended September 26, 2026GAAP$384M–(60.7) %
Diluted earnings per share attributable to Medline Inc., nine months ended September 26, 2026GAAP$ 0.45––
Adjusted EBITDA, nine months ended September 26, 2026non-GAAP$2.80B–5.0 %
Adjusted EBITDA Margin, nine months ended September 26, 2026non-GAAP12.2 %––
Adjusted Net Income, nine months ended September 26, 2026non-GAAP$1.68B––
Adjusted Diluted EPS, nine months ended September 26, 2026non-GAAP$ 1.27––
Net cash provided by operating activities, nine months ended September 26, 2026GAAP$2.15B–42.0 %
Free Cash Flow, nine months ended September 26, 2026non-GAAP$1.80B–49.6 %
Net capital expenditures, nine months ended September 26, 2026GAAP−$348M–12.6 %
Net Leverage, trailing twelve months ended September 26, 2026non-GAAP2.5––

Segments

SegmentRevenueq/qy/y
Medline Brand segment, three months ended September 26, 2026The release states that net sales growth was primarily driven by existing customer growth and implementation of new customer signings from 2025.$3.64B–6.6 %
Supply Chain Solutions segment, three months ended September 26, 2026The release states that net sales growth was primarily driven by existing customer growth and implementation of new customer signings from 2025.$4.22B–13.9 %
Medline Brand segment, nine months ended September 26, 2026The release states that nine-month sales growth was primarily driven by implementation of new customer signings from 2025 and existing customer growth.$10.64B–6.5 %
Supply Chain Solutions segment, nine months ended September 26, 2026The release states that nine-month sales growth was primarily driven by implementation of new customer signings from 2025 and existing customer growth.$12.25B–15.1 %

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

full year 2026 outlook

  • NoteOrganic Sales growth: 10.0% to 10.5%
  • NoteAdjusted EBITDA: $3.3 billion to $3.4 billion
  • NoteGuidance for full year 2026 Adjusted EBITDA excludes $324 million of net tariff refunds through the first nine months of 2026.

Capital returns

  • In October, the Medline Board of Directors approved a share repurchase program authorizing the Company, including Medline Holdings, LP, to repurchase up to $1 billion of the Company’s outstanding shares of Class A common stock and/or units of Medline Holdings, LP.
  • The Company prepaid $750 million in aggregate principal amount of the 2033 Refinancing Term Loan Facility.

What drove it

  • Third quarter net sales growth was primarily driven by existing customer growth and implementation of new customer signings from 2025.
  • Nine-month net sales growth was primarily driven by implementation of new customer signings from 2025 and existing customer growth.
  • Third quarter Adjusted EBITDA growth was primarily driven by higher net sales and net IEEPA tariff refund benefits.
  • The Company recognized $81 million and $324 million of net IEEPA tariff refund benefits during the three and nine months ended September 26, 2026, respectively.
  • Free Cash Flow was driven by net cash provided by operating activities and was partially offset by $348 million of capital expenditures.

Concerns

  • Third quarter gross margin was 24.5 %, compared to 26.4 % in the prior-year quarter.
  • Nine-month gross margin was 26.1 %, compared to 27.1 % in the prior-year period.
  • Nine-month operating income decreased 26.3 % to $ 1,317 (in millions), and net income decreased 28.8 % to $ 696 (in millions).
  • The Company reported net losses of $316 million related to the fire at its distribution center in Tracy, California during the first nine months of 2026.
  • The Company cited higher operating expenses, higher cost of goods sold including the impact of tariffs, customer and segment mix, and increased inventory costs associated with inflation as nine-month net-income pressures.
  • Supply Chain Solutions segment Adjusted EBITDA decreased 10.2 % in the third quarter and 2.2 % for the nine-month period.

What to watch

  • Delivery against full year 2026 Organic Sales growth guidance of 10.0% to 10.5%.
  • Delivery against full year 2026 Adjusted EBITDA guidance of $3.3 billion to $3.4 billion, which excludes $324 million of net tariff refunds through the first nine months of 2026.
  • Progress toward the annual total new customer signings goal and implementation of customer signings from 2025.
  • The ongoing effect of the Tracy, California distribution center fire, net of insurance proceeds.
  • Gross-margin performance amid inventory costs associated with inflation, tariffs, and customer and segment mix.
  • Execution of investments in distribution automation, new distribution centers, and kitting manufacturing-capacity expansion.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 26, 2026: $ 2,321 (in millions).
  • Short-term investments as of September 26, 2026: $ 1,287 (in millions).
  • Total debt as of September 26, 2026: $ 12,743 (in millions).
  • Net debt as of September 26, 2026: $ 9,135 (in millions).
  • Net cash provided by operating activities for the first nine months of 2026: $2.2 billion.
  • Free Cash Flow for the first nine months of 2026: $1.8 billion.
  • Net cash used in investing activities, nine months ended September 26, 2026: $ (1,537) (in millions), compared to $ (336) (in millions).
  • Net cash used in financing activities, nine months ended September 26, 2026: $ (220) (in millions), compared to $ (498) (in millions).

Analysis

Medline reported broad top-line momentum in the third quarter and first nine months of 2026. Third-quarter net sales increased 10.4% and Organic Sales increased 10.5%, while nine-month net sales increased 10.9% and Organic Sales increased 10.7%. Management attributed growth to existing customer growth and implementation of new customer signings from 2025. Supply Chain Solutions grew faster than Medline Brand in both reported periods, with segment net-sales growth of 13.9% in the quarter and 15.1% for nine months.

The sales growth did not fully translate into GAAP profit expansion. Third-quarter gross margin was 24.5 %, versus 26.4 % a year earlier, and operating income declined 12.9 %. Nine-month gross margin was 26.1 %, versus 27.1 %, while operating income declined 26.3 % and net income declined 28.8 %. The company cited increased inventory costs associated with inflation, higher operating expenses, customer and segment mix, and higher cost of goods sold including tariffs. The nine-month period also included net losses of $316 million related to the Tracy, California distribution center fire.

Non-GAAP earnings were stronger than GAAP earnings. Third-quarter Adjusted EBITDA increased 11.8 % to $ 960 (in millions), and its margin increased to 12.2 % from 12.1 %. Nine-month Adjusted EBITDA increased 5.0 % to $ 2,796 (in millions), although Adjusted EBITDA Margin declined to 12.2 % from 12.9 %. Medline reported net IEEPA tariff refund benefits of $81 million in the quarter and $324 million in the nine-month period. These benefits were included in net income and Adjusted EBITDA, but full-year Adjusted EBITDA guidance excludes the $324 million of net tariff refunds through the first nine months.

Cash generation was a positive feature of the release. Nine-month operating cash flow rose 42.0 % to $ 2,152 (in millions), and Free Cash Flow rose 49.6 % to $ 1,804 (in millions), after $ (348) (in millions) of net capital expenditures. The company reported cash and cash equivalents of $ 2,321 (in millions), short-term investments of $ 1,287 (in millions), total debt of $ 12,743 (in millions), net debt of $ 9,135 (in millions), and Net Leverage of 2.5. Capital allocation included authorization of up to $1 billion in share repurchases and prepayment of $750 million of the 2033 Refinancing Term Loan Facility.

Management raised full-year Organic Sales growth guidance to 10.0% to 10.5% from 9.0% to 10.0% while reaffirming Adjusted EBITDA guidance of $3.3 billion to $3.4 billion. The revised sales outlook reflects continuing commercial momentum, while the unchanged EBITDA outlook keeps attention on margin pressure, the impact of tariffs and inflation, customer and segment mix, and costs associated with the Tracy facility fire. Investors will also monitor whether Supply Chain Solutions can restore Adjusted EBITDA growth after declines in both reported periods.

Management, verbatim

Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business.

Jim Boyle, chief executive officer of Medline

Our commercial execution remains strong, including continued progress toward our annual total new customer signings goal.

Jim Boyle, chief executive officer of Medline

Not in the filing

stated, not guessed
  • Quarterly operating cash flow and quarterly Free Cash Flow were not reported.
  • Dividend amount and dividend declaration were not reported.
  • Forward guidance for revenue, gross margin, operating expenses, and tax rate was not reported.
  • Prior-year basic and diluted earnings per share attributable to Medline Inc. were reported as N/A.
  • Prior-year Adjusted Net Income and Adjusted Diluted EPS were not reported.
  • The previous outlook covered the full year 2026 only, and this release reports the third quarter and nine months, so there is no comparable guidance for this period.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter and First Six Months 2026

AlphAI · Earnings readMDLN · Second Quarter and First Six Months 2026 · ended June 27, 2026

Second-quarter net sales increased 11.6% to $7.7 billion and Adjusted EBITDA increased 13.4% to $1,060 million, while net income decreased 58.3% to $139 million; full-year Organic Sales guidance was raised and Adjusted EBITDA guidance was reduced.

→Mixed half-year

Strong sales growth, organic growth, and second-quarter Adjusted EBITDA growth were offset by a substantial decline in net income related primarily to the Tracy, California distribution center fire. The Company raised its Organic Sales outlook but lowered its Adjusted EBITDA outlook.

Revenue
$15B
11.1% y/y
EPS · non-GAAP
$0.83

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Second quarter 2026 net salesGAAP$7.7B–11.6%
Second quarter 2026 Organic Salesnon-GAAP11.5%––
Second quarter 2026 net incomeGAAP$139M–(58.3%)
Second quarter 2026 Adjusted EBITDAnon-GAAP$1.06B–13.4%
Second quarter 2026 diluted earnings per shareGAAP$0.07––
Second quarter 2026 Adjusted Diluted EPSnon-GAAP$0.50––
First six months 2026 net salesGAAP$15B–11.1%
First six months 2026 Organic Salesnon-GAAP10.8%––
First six months 2026 net incomeGAAP$378M–(42.3%)
First six months 2026 Adjusted EBITDAnon-GAAP$1.84B–1.9%
First six months 2026 diluted earnings per shareGAAP$0.23––
First six months 2026 Adjusted Diluted EPSnon-GAAP$0.83––
IEEPA tariff refundsGAAP$332M––
Accrued customer repayments associated with IEEPA tariff refundsGAAP$89M––
Net IEEPA tariff refund benefitsGAAP$243M––
Net cash provided by operating activities for the first six months 2026GAAP$1.1B––
Free Cash Flow for the first six months 2026non-GAAP$920M––
Capital expenditures for the first six months 2026GAAP$207M––

full year 2026 outlook

  • NoteOrganic Sales growth: 9.0% to 10.0%
  • NoteAdjusted EBITDA: $3.3 billion to $3.4 billion
  • NoteThe Organic Sales outlook includes IEEPA tariff customer repayments.
  • NoteThe Adjusted EBITDA outlook does not reflect the benefit of IEEPA tariff refunds.

What drove it

  • Second-quarter and first-six-month net sales growth was primarily driven by existing customer growth and implementation of new customer signings from 2025.
  • Second-quarter Adjusted EBITDA growth was primarily driven by higher net sales and net IEEPA tariff refund benefits.
  • The Company secured over 65% of its annual goal in total new customer signings during the first half of 2026.
  • The full-year Organic Sales outlook increase reflects strong existing and new customer demand.
  • IEEPA tariff refunds and related customer repayments were recorded entirely within the Medline Brand segment.

Concerns

  • Second-quarter and first-six-month net income included losses of $336 million related to the Tracy, California distribution center fire, before expected insurance recoveries.
  • Higher operating expenses and higher cost of goods sold, including the impact of tariffs, pressured second-quarter and first-six-month net income and Adjusted EBITDA.
  • The lowered Adjusted EBITDA outlook primarily reflects higher than expected inflationary pressure from the Middle East conflict, increased operational investments to support customer demand, quality remediation efforts, and retail channel softness.
  • The Company accrued $89 million of customer repayments associated with IEEPA tariff refunds as a reduction of net sales.

What to watch

  • Execution of the full-year 2026 Organic Sales growth outlook of 9.0% to 10.0%.
  • Delivery against the full-year 2026 Adjusted EBITDA outlook of $3.3 billion to $3.4 billion.
  • The operational and financial impact of the Tracy, California distribution center fire and expected insurance recoveries.
  • Inflationary pressure from the Middle East conflict, operational investments, quality remediation efforts, and retail channel softness.
  • The impact of IEEPA tariff customer repayments on Organic Sales and the exclusion of IEEPA tariff refund benefits from the Adjusted EBITDA outlook.

Balance sheet and cash flow

  • Net cash provided by operating activities for the first six months 2026 was $1.1 billion.
  • Free Cash Flow for the first six months 2026 was $920 million.
  • Capital expenditures were $207 million, primarily related to continued enhancements and automation in the Company’s distribution centers and investments in its kitting manufacturing facilities.

Analysis

Medline reported strong top-line momentum in the second quarter, with net sales increasing 11.6% to $7.7 billion and Organic Sales increasing 11.5%. For the first six months, net sales increased 11.1% to $15.0 billion and Organic Sales increased 10.8%. Management attributed growth in both periods primarily to existing customer growth and implementation of new customer signings from 2025. The Company also stated that it secured over 65% of its annual goal in total new customer signings during the first half of 2026.

Profitability was materially affected by the Tracy, California distribution center fire. Second-quarter net income decreased 58.3% to $139 million, while first-six-month net income decreased 42.3% to $378 million. The Company cited $336 million of losses related to the fire, before expected insurance recoveries, alongside higher operating expenses and higher cost of goods sold including tariffs. These factors were partially offset by higher sales and net IEEPA tariff refund benefits.

Adjusted EBITDA increased 13.4% to $1,060 million in the second quarter, but first-six-month Adjusted EBITDA increased only 1.9% to $1.84 billion. Both periods included $243 million of net IEEPA tariff refund benefits, consisting of $332 million of tariff refunds recorded as a reduction of cost of goods sold, partly offset by $89 million of accrued customer repayments recorded as a reduction of net sales. The Company stated that these amounts were recorded entirely in the Medline Brand segment.

Cash generation was supported by operations during the first six months, with net cash provided by operating activities of $1.1 billion and Free Cash Flow of $920 million. Capital expenditures of $207 million were directed primarily to distribution-center enhancements and automation and investments in kitting manufacturing facilities. No capital-return activity, cash balance, or debt balance was reported in the supplied filing text.

Management raised its full-year 2026 Organic Sales growth outlook to 9.0% to 10.0% from 8.5% to 9.5%, citing strong existing and new customer demand. It reduced the Adjusted EBITDA outlook to $3.3 billion to $3.4 billion from $3.5 to $3.6 billion, citing higher than expected inflationary pressure from the Middle East conflict, increased operational investments, quality remediation efforts, and retail channel softness. The Organic Sales outlook includes IEEPA tariff customer repayments, while the Adjusted EBITDA outlook excludes the benefit of IEEPA tariff refunds.

Management, verbatim

Our second quarter results reflect strong execution of our growth strategy, and the operational resilience of our team.

Jim Boyle, chief executive officer of Medline

We delivered robust top-line growth in the quarter, secured over 65% of our annual goal in total new customer signings 4 during the first half of 2026, and moved swiftly to minimize disruption from the fire at our Tracy, California distribution center, demonstrating an unwavering commitment to our customers.

Jim Boyle, chief executive officer of Medline

Not in the filing

stated, not guessed
  • Segment revenue, segment growth rates, and segment-specific drivers beyond the statement that IEEPA tariff amounts were recorded entirely within the Medline Brand segment.
  • Gross profit and gross margin.
  • Operating income and operating margin.
  • GAAP and non-GAAP income-tax rate.
  • Prior-year diluted earnings per share and Adjusted Diluted EPS.
  • Prior-quarter comparisons for reported metrics.
  • Cash balance.
  • Debt balance and net leverage.
  • Share repurchases, dividends, and other capital-return activity.
  • Forward guidance for total revenue, gross margin, operating expenses, and tax rate.
  • A separately provided previous outlook section for formal actual-versus-prior-guidance comparison.
  • Full non-GAAP reconciliations and underlying financial-statement line items are not included in the supplied filing text.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about MDLN earnings dates

When is Medline's next earnings date?
AlphAI has no date for MDLN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.